STIB HPR score allows identification of patients with a high probability of resistance to clopidogrel based on diabetes, Hb 28kg/m². This bedside clinical test could be useful for the indentification of patients in whom another P2Y12 inhibitor should be recommended before and after PCI
Clinical studies suggest that 10-50% of patients are resistant to clopidogrel therapy. ADP induced p...
ObjectivesThis study aimed to explore platelet function tests relevant to the biological effects of ...
INTRODUCTION: There is potential value in testing individual response to P2Y12 inhibitors to predict...
BACKGROUND: High platelet reactivity (HPR) to clopidogrel is associated with an increased risk of is...
High platelet reactivity (HPR) to clopidogrel is associated with an increased risk of ischaemic comp...
The phenomenon of resistance to copidogrel catches the attention of a growing number of clinicians b...
Antiplatelet agents are mainly used in the prevention and management of atherothrombotic complicatio...
Background: Multiple platelet function tests claim to be P2Y12-pathway specific and capable of captu...
BackgroundClopidogrel low response correlates with poor prognosis after percutaneous coronary interv...
PURPOSE: The POPular Risk Score was developed for the selective intensification of P2Y 12 inhibitor ...
Aspirin and clopidogrel are proven to prevent thromboembolic events during percutaneous coronary int...
ObjectivesThe aim of this study was to determine whether low platelet response to the P2Y12 receptor...
BACKGROUND: Dual antiplatelet therapy (APD) is the cornerstone of management of coronary artery dise...
The P2Y12 inhibitors, clopidogrel, prasugrel, and ticagrelor, are administered in fixed doses withou...
<p>Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance i...
Clinical studies suggest that 10-50% of patients are resistant to clopidogrel therapy. ADP induced p...
ObjectivesThis study aimed to explore platelet function tests relevant to the biological effects of ...
INTRODUCTION: There is potential value in testing individual response to P2Y12 inhibitors to predict...
BACKGROUND: High platelet reactivity (HPR) to clopidogrel is associated with an increased risk of is...
High platelet reactivity (HPR) to clopidogrel is associated with an increased risk of ischaemic comp...
The phenomenon of resistance to copidogrel catches the attention of a growing number of clinicians b...
Antiplatelet agents are mainly used in the prevention and management of atherothrombotic complicatio...
Background: Multiple platelet function tests claim to be P2Y12-pathway specific and capable of captu...
BackgroundClopidogrel low response correlates with poor prognosis after percutaneous coronary interv...
PURPOSE: The POPular Risk Score was developed for the selective intensification of P2Y 12 inhibitor ...
Aspirin and clopidogrel are proven to prevent thromboembolic events during percutaneous coronary int...
ObjectivesThe aim of this study was to determine whether low platelet response to the P2Y12 receptor...
BACKGROUND: Dual antiplatelet therapy (APD) is the cornerstone of management of coronary artery dise...
The P2Y12 inhibitors, clopidogrel, prasugrel, and ticagrelor, are administered in fixed doses withou...
<p>Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance i...
Clinical studies suggest that 10-50% of patients are resistant to clopidogrel therapy. ADP induced p...
ObjectivesThis study aimed to explore platelet function tests relevant to the biological effects of ...
INTRODUCTION: There is potential value in testing individual response to P2Y12 inhibitors to predict...
DOI
Add to ORKG